Changes of Mycobacterium tuberculosis specific antigen-stimulated CD27 - CD38 + IFN-γ + CD4 + T cells before and after anti-tuberculosis treatment
The aim of the study was to investigate whether the expression of CD27 CD38 in interferon (IFN)-γ CD4 T cells stimulated by the specific antigen early secreted antigenic target-6 (ESAT-6)/culture filter protein-10 (CFP-10) could be a potential new therapeutic evaluation indicator for anti-tuberculos...
Gespeichert in:
Veröffentlicht in: | European journal of medical research 2024-03, Vol.29 (1), p.147-147, Article 147 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The aim of the study was to investigate whether the expression of CD27
CD38
in interferon (IFN)-γ
CD4
T cells stimulated by the specific antigen early secreted antigenic target-6 (ESAT-6)/culture filter protein-10 (CFP-10) could be a potential new therapeutic evaluation indicator for anti-tuberculosis (TB) treatment.
Newly diagnosed active pulmonary TB patients, latent TB infection (LTBI) and healthy controls were enrolled from January 2021 to December 2021. PTB patients were treated by standard anti-TB regimen 2HREZ/4HR (2 months of isoniazid (H), rifampin (R), ethambutol (E), and pyrazinamide (Z) followed by 4 months of isoniazid (H) and rifampin (R)). The difference of CD27
CD38
expression in IFN-γ
CD4
T cells before treatment, 2 months after treatment, and 6 months after treatment were compared.
Total 45 PTB patients, 38 LTBI cases and 43 healthy controls were enrolled. The expression of CD27
CD38
decreased significantly after anti-TB treatment and was comparable with that in LTBI and healthy controls when the 6-month anti-TB treatment course was completed. The decline rate of CD27
CD38
between 6 months after treatment and baseline was positively correlated with erythrocyte sedimentation rate (r = 0.766, P |
---|---|
ISSN: | 2047-783X 0949-2321 2047-783X |
DOI: | 10.1186/s40001-024-01713-x |